CIBC Bancorp USA
NVCT icon

CIBC Bancorp USA’s Nuvectis Pharma NVCT Stock Holding History

CIBC Bancorp USA’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.6M Buy
2,067
+1,123
+119% +$23.7K ﹤0.01% 994
2026
Q2 		$918K Buy
944
+165
+21% +$1.85K ﹤0.01% 1124
2026
Q1 		$198K Buy
+779
New +$6.67K ﹤0.01% 1623

Other funds holding NVCT

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Iridian Asset Management
Iridian Asset Management Westport, Connecticut $275M AUM 37.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Baldwin Wealth Partners
Baldwin Wealth Partners Marion, Massachusetts $1.52B AUM 21.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Occam Crest Management
Occam Crest Management Darien, Connecticut $188M AUM 69.74% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

CIBC Bancorp USA's NVCT Position: Q3 2026 in Review

CIBC Bancorp USA increased its Nuvectis Pharma (NVCT) stake by 119% in Q3 2026, buying an estimated $23.7K and bringing the position to 2,067 shares worth $1.6M. The position accounts for ﹤0.01% of the portfolio, ranked #994.

CIBC Bancorp USA first reported a position in NVCT in Q1 2026 and has held it in 3 quarters since. 65 funds tracked by Wall St. Rank hold NVCT as of Q3 2026.

  • CIBC Bancorp USA held 2,067 shares of Nuvectis Pharma worth $1.6M as of Q3 2026.
  • CIBC Bancorp USA bought 1,123 Nuvectis Pharma shares in Q3 2026, an estimated $23.7K.
  • Nuvectis Pharma made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2026, its #994 holding.
  • CIBC Bancorp USA first reported a position in Nuvectis Pharma in Q1 2026 and has held it in 3 quarters since.
  • 65 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q3 2026.

Based on CIBC Bancorp USA's 13F filing for Q3 2026, filed 13 Nov 2026.